Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that is used as a prescription medication in Hong Kong. It belongs to the Digestive Health therapeutic class and is supplied as a 300 mg pill. In many markets UDCA is marketed under brand names such as Urso, Actigall, and Urso Forte, but the active ingredient is identical across products. The drug is regulated by the Hong Kong Department of Health and requires a medical prescription.
Ursodeoxycholic acid is a hydrophilic bile acid that alters the composition of the bile-acid pool. Its main actions are:
These mechanisms together help improve liver function in cholestatic diseases and support the breakdown of certain gallstones.
Ursodeoxycholic acid is approved by the Hong Kong regulatory authorities for the following indications:
The medication may also be prescribed for other cholestatic liver disorders when a clinician judges the benefit outweighs any risk.
Ursodeoxycholic acid has been investigated for several conditions beyond its official labeling. Where scientific literature provides reasonable evidence, the following off-label uses are noted, with the required disclaimer:
Off-label use requires medical supervision and individualized risk assessment.
Patients with any of these conditions should discuss alternatives with their healthcare provider.
Patients should disclose all prescription drugs, over-the-counter products, supplements, and herbal preparations before starting UDCA.
Regular follow-up with a hepatologist or gastroenterologist is recommended for all patients on long-term UDCA therapy.
This article provides educational information about ursodeoxycholic acid and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Ursodeoxycholic acid is usually prescribed at 13-15 mg per kilogram of body weight per day, divided into two or three doses. For a 70 kg adult, this equates to about 900-1050 mg daily, or three to four 300 mg tablets.
UDCA is effective primarily for small cholesterol gallstones (<15 mm) when the gallbladder remains functional. It does not work on pigment stones or large cholesterol stones, and surgical removal may still be required.
The drug is approved for intra-hepatic cholestasis of pregnancy, but use in the first trimester should be limited to cases where the benefits clearly outweigh potential risks, and always under specialist supervision.
Patients often notice a reduction in itching within 2-4 weeks of starting therapy, although individual response times vary. Ongoing monitoring of liver enzymes helps gauge overall effectiveness.
The medication can be taken with or without meals. Some patients find taking it with food reduces gastrointestinal discomfort, but adherence to the prescribed schedule is more important than timing with meals.
Yes. Cholestyramine binds bile acids in the gut and can significantly reduce UDCA absorption. To avoid this interaction, separate the doses by at least two hours.
Baseline and periodic liver function tests (ALT, AST, ALP, bilirubin) are recommended to monitor therapeutic response and detect any potential hepatotoxicity.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of the destination country’s rules regarding import of prescription drugs.
Ursodeoxycholic acid is sold as a generic medication in Hong Kong, typically marketed under various brand names but containing the same 300 mg active ingredient.
Do not flush the tablets down the toilet. Follow local pharmacy or municipal guidelines for medication disposal, such as returning them to a designated drug-take-back program or using a sealed container placed in household trash.
